Nuvectis Pharma initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen initiated coverage of Nuvectis Pharma (NVCT) with a Buy rating and $19 price target Nuvectis is an early to ...
AstraZeneca to Buy EsoBiotec for up to $1 Billion
AstraZeneca will buy all outstanding equity of EsoBiotec for on a cash and debt-free basis, which includes an initial payment ...